Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Novel correlates of protection against pandemic H1N1 influenza A virus infection.

Ng S, Nachbagauer R, Balmaseda A, Stadlbauer D, Ojeda S, Patel M, Rajabhathor A, Lopez R, Guglia AF, Sanchez N, Amanat F, Gresh L, Kuan G, Krammer F, Gordon A.

Nat Med. 2019 Jun;25(6):962-967. doi: 10.1038/s41591-019-0463-x. Epub 2019 Jun 3.

PMID:
31160818
2.

An HER2-Displaying Virus-Like Particle Vaccine Protects from Challenge with Mammary Carcinoma Cells in a Mouse Model.

Nika L, Cuadrado-Castano S, Asthagiri Arunkumar G, Grünwald-Gruber C, McMahon M, Koczka K, García-Sastre A, Krammer F, Grabherr R.

Vaccines (Basel). 2019 May 20;7(2). pii: E41. doi: 10.3390/vaccines7020041.

3.

Mucosal Immunity against Neuraminidase Prevents Influenza B Virus Transmission in Guinea Pigs.

McMahon M, Kirkpatrick E, Stadlbauer D, Strohmeier S, Bouvier NM, Krammer F.

MBio. 2019 May 21;10(3). pii: e00560-19. doi: 10.1128/mBio.00560-19.

4.

Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model.

Liu WC, Nachbagauer R, Stadlbauer D, Solórzano A, Berlanda-Scorza F, García-Sastre A, Palese P, Krammer F, Albrecht RA.

Front Immunol. 2019 Apr 10;10:756. doi: 10.3389/fimmu.2019.00756. eCollection 2019.

5.

Dengue and Zika: The Complexities of Being Related.

Krammer F, Lim JK.

Trends Immunol. 2019 Jun;40(6):467-469. doi: 10.1016/j.it.2019.04.008. Epub 2019 May 6.

PMID:
31072687
6.

Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice.

Choi A, Bouzya B, Cortés Franco KD, Stadlbauer D, Rajabhathor A, Rouxel RN, Mainil R, Van der Wielen M, Palese P, García-Sastre A, Innis BL, Krammer F, Schotsaert M, Mallett CP, Nachbagauer R.

Immunohorizons. 2019 Apr 1;3(4):133-148. doi: 10.4049/immunohorizons.1900022.

7.

Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine.

Matsuda K, Huang J, Zhou T, Sheng Z, Kang BH, Ishida E, Griesman T, Stuccio S, Bolkhovitinov L, Wohlbold TJ, Chromikova V, Cagigi A, Leung K, Andrews S, Cheung CSF, Pullano AA, Plyler J, Soto C, Zhang B, Yang Y, Joyce MG, Tsybovsky Y, Wheatley A, Narpala SR, Guo Y, Darko S, Bailer RT, Poole A, Liang CJ, Smith J, Alexander J, Gurwith M, Migueles SA, Koup RA, Golding H, Khurana S, McDermott AB, Shapiro L, Krammer F, Kwong PD, Connors M.

Sci Immunol. 2019 Apr 19;4(34). pii: eaau2710. doi: 10.1126/sciimmunol.aau2710.

PMID:
31004012
8.

20th International Conference on Emerging Infectious Diseases in the Pacific Rim Organized by the United States-Japan Cooperative Medical Sciences Program (USJCMSP).

USJCMSP AIDS, ARI, Cancer, Hepatitis, Immunology and Viral Diseases Panels, Bernabe KG, Lu KT, Handley FG, Griffin DE, Kurane I, Iwamoto A, Gao GF, Krammer F.

Vaccines (Basel). 2019 Apr 2;7(2). pii: E35. doi: 10.3390/vaccines7020035.

9.

Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.

Sun W, Kirkpatrick E, Ermler M, Nachbagauer R, Broecker F, Krammer F, Palese P.

J Virol. 2019 May 29;93(12). pii: e00333-19. doi: 10.1128/JVI.00333-19. Print 2019 Jun 15.

PMID:
30944178
10.

Antibodies Elicited by an NS1-Based Vaccine Protect Mice against Zika Virus.

Bailey MJ, Broecker F, Duehr J, Arumemi F, Krammer F, Palese P, Tan GS.

MBio. 2019 Apr 2;10(2). pii: e02861-18. doi: 10.1128/mBio.02861-18.

11.

Cross-reactive antibodies binding to H4 hemagglutinin protect against a lethal H4N6 influenza virus challenge in the mouse model.

Amanat F, Meade P, Strohmeier S, Krammer F.

Emerg Microbes Infect. 2019;8(1):155-168. doi: 10.1080/22221751.2018.1564369.

12.

The human antibody response to influenza A virus infection and vaccination.

Krammer F.

Nat Rev Immunol. 2019 Jun;19(6):383-397. doi: 10.1038/s41577-019-0143-6. Review.

PMID:
30837674
13.

Influenza Virus Vaccination Elicits Poorly Adapted B Cell Responses in Elderly Individuals.

Henry C, Zheng NY, Huang M, Cabanov A, Rojas KT, Kaur K, Andrews SF, Palm AE, Chen YQ, Li Y, Hoskova K, Utset HA, Vieira MC, Wrammert J, Ahmed R, Holden-Wiltse J, Topham DJ, Treanor JJ, Ertl HC, Schmader KE, Cobey S, Krammer F, Hensley SE, Greenberg H, He XS, Wilson PC.

Cell Host Microbe. 2019 Mar 13;25(3):357-366.e6. doi: 10.1016/j.chom.2019.01.002. Epub 2019 Feb 19.

PMID:
30795982
14.

MHC class II proteins mediate cross-species entry of bat influenza viruses.

Karakus U, Thamamongood T, Ciminski K, Ran W, Günther SC, Pohl MO, Eletto D, Jeney C, Hoffmann D, Reiche S, Schinköthe J, Ulrich R, Wiener J, Hayes MGB, Chang MW, Hunziker A, Yángüez E, Aydillo T, Krammer F, Oderbolz J, Meier M, Oxenius A, Halenius A, Zimmer G, Benner C, Hale BG, García-Sastre A, Beer M, Schwemmle M, Stertz S.

Nature. 2019 Mar;567(7746):109-112. doi: 10.1038/s41586-019-0955-3. Epub 2019 Feb 20.

PMID:
30787439
15.

Fighting influenza through hemagglutinin diversity.

Krammer F.

Nat Immunol. 2019 Mar;20(3):246-247. doi: 10.1038/s41590-019-0317-1. No abstract available.

PMID:
30742079
16.

Dengue Virus Immunity Increases Zika Virus-Induced Damage during Pregnancy.

Brown JA, Singh G, Acklin JA, Lee S, Duehr JE, Chokola AN, Frere JJ, Hoffman KW, Foster GA, Krysztof D, Cadagan R, Jacobs AR, Stramer SL, Krammer F, García-Sastre A, Lim JK.

Immunity. 2019 Mar 19;50(3):751-762.e5. doi: 10.1016/j.immuni.2019.01.005. Epub 2019 Feb 5.

PMID:
30737148
17.

Broad Hemagglutinin-Specific Memory B Cell Expansion by Seasonal Influenza Virus Infection Reflects Early-Life Imprinting and Adaptation to the Infecting Virus.

Tesini BL, Kanagaiah P, Wang J, Hahn M, Halliley JL, Chaves FA, Nguyen PQT, Nogales A, DeDiego ML, Anderson CS, Ellebedy AH, Strohmeier S, Krammer F, Yang H, Bandyopadhyay S, Ahmed R, Treanor JJ, Martinez-Sobrido L, Golding H, Khurana S, Zand MS, Topham DJ, Sangster MY.

J Virol. 2019 Apr 3;93(8). pii: e00169-19. doi: 10.1128/JVI.00169-19. Print 2019 Apr 15.

PMID:
30728266
18.

Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain.

Krammer F, Palese P.

J Infect Dis. 2019 Apr 8;219(Supplement_1):S62-S67. doi: 10.1093/infdis/jiy711.

PMID:
30715353
19.

Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice.

Asthagiri Arunkumar G, Ioannou A, Wohlbold TJ, Meade P, Aslam S, Amanat F, Ayllon J, García-Sastre A, Krammer F.

J Virol. 2019 Mar 5;93(6). pii: e01696-18. doi: 10.1128/JVI.01696-18. Print 2019 Mar 15.

PMID:
30626682
20.

Protein Microarray Analysis of the Specificity and Cross-Reactivity of Influenza Virus Hemagglutinin-Specific Antibodies.

Nakajima R, Supnet M, Jasinskas A, Jain A, Taghavian O, Obiero J, Milton DK, Chen WH, Grantham M, Webby R, Krammer F, Carter D, Felgner PL, Davies DH.

mSphere. 2018 Dec 12;3(6). pii: e00592-18. doi: 10.1128/mSphere.00592-18.

21.

Erratum: Sunwoo, S.-Y. et al. A Universal Influenza Virus Vaccine Candidate Tested in a Pig Vaccination-Infection Model in the Presence of Maternal Antibodies. Vaccines 2018, 6(3), 64.

Sunwoo SY, Schotsaert M, Morozov I, Davis AS, Li Y, Lee J, McDowell C, Meade P, Nachbagauer R, García-Sastre A, Ma W, Krammer F, Richt JA.

Vaccines (Basel). 2018 Nov 27;6(4). pii: E80. doi: 10.3390/vaccines6040080.

22.

Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model.

Bailey MJ, Duehr J, Dulin H, Broecker F, Brown JA, Arumemi FO, Bermúdez González MC, Leyva-Grado VH, Evans MJ, Simon V, Lim JK, Krammer F, Hai R, Palese P, Tan GS.

Nat Commun. 2018 Nov 1;9(1):4560. doi: 10.1038/s41467-018-07008-0.

23.

Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans.

Sun W, Kang DS, Zheng A, Liu STH, Broecker F, Simon V, Krammer F, Palese P.

J Virol. 2019 Jan 4;93(2). pii: e01673-18. doi: 10.1128/JVI.01673-18. Print 2019 Jan 15.

PMID:
30381487
24.

A Universal Influenza Virus Vaccine Candidate Tested in a Pig Vaccination-Infection Model in the Presence of Maternal Antibodies.

Sunwoo SY, Schotsaert M, Morozov I, Davis AS, Li Y, Lee J, McDowell C, Meade P, Nachbagauer R, García-Sastre A, Ma W, Krammer F, Richt JA.

Vaccines (Basel). 2018 Sep 14;6(3). pii: E64. doi: 10.3390/vaccines6030064. Erratum in: Vaccines (Basel). 2018 Nov 27;6(4):.

25.

Editorial overview: Tough targets.

Krammer F, Wilson PC.

Curr Opin Immunol. 2018 Aug;53:iv-vi. doi: 10.1016/j.coi.2018.08.005. No abstract available.

PMID:
30220352
26.

Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance.

Liu STH, Behzadi MA, Sun W, Freyn AW, Liu WC, Broecker F, Albrecht RA, Bouvier NM, Simon V, Nachbagauer R, Krammer F, Palese P.

J Clin Invest. 2018 Nov 1;128(11):4992-4996. doi: 10.1172/JCI122895. Epub 2018 Oct 8.

27.

Assessment of Influenza Virus Hemagglutinin Stalk-Specific Antibody Responses.

Liu WC, Nachbagauer R, Krammer F, Albrecht RA.

Methods Mol Biol. 2018;1836:487-511. doi: 10.1007/978-1-4939-8678-1_23.

PMID:
30151588
28.

Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies.

Pardi N, Parkhouse K, Kirkpatrick E, McMahon M, Zost SJ, Mui BL, Tam YK, Karikó K, Barbosa CJ, Madden TD, Hope MJ, Krammer F, Hensley SE, Weissman D.

Nat Commun. 2018 Aug 22;9(1):3361. doi: 10.1038/s41467-018-05482-0.

29.

Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection.

Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, Halfmann PJ, Brannan JM, Herbert AS, Qiu X, Wagh K, He S, Giorgi EE, Theiler J, Pommert KBJ, Krause TB, Turner HL, Murin CD, Pallesen J, Davidson E, Ahmed R, Aman MJ, Bukreyev A, Burton DR, Crowe JE Jr, Davis CW, Georgiou G, Krammer F, Kyratsous CA, Lai JR, Nykiforuk C, Pauly MH, Rijal P, Takada A, Townsend AR, Volchkov V, Walker LM, Wang CI, Zeitlin L, Doranz BJ, Ward AB, Korber B, Kobinger GP, Andersen KG, Kawaoka Y, Alter G, Chandran K, Dye JM; Viral Hemorrhagic Fever Immunotherapeutic Consortium.

Cell. 2018 Aug 9;174(4):938-952.e13. doi: 10.1016/j.cell.2018.07.033.

30.

Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice.

Broecker F, Liu STH, Sun W, Krammer F, Simon V, Palese P.

J Virol. 2018 Sep 26;92(20). pii: e01100-18. doi: 10.1128/JVI.01100-18. Print 2018 Oct 15.

31.
32.

The influenza virus hemagglutinin head evolves faster than the stalk domain.

Kirkpatrick E, Qiu X, Wilson PC, Bahl J, Krammer F.

Sci Rep. 2018 Jul 11;8(1):10432. doi: 10.1038/s41598-018-28706-1.

33.

Direct Visualization of the Conformational Dynamics of Single Influenza Hemagglutinin Trimers.

Das DK, Govindan R, Nikić-Spiegel I, Krammer F, Lemke EA, Munro JB.

Cell. 2018 Aug 9;174(4):926-937.e12. doi: 10.1016/j.cell.2018.05.050. Epub 2018 Jun 28.

PMID:
29961575
34.

Influenza.

Krammer F, Smith GJD, Fouchier RAM, Peiris M, Kedzierska K, Doherty PC, Palese P, Shaw ML, Treanor J, Webster RG, García-Sastre A.

Nat Rev Dis Primers. 2018 Jun 28;4(1):3. doi: 10.1038/s41572-018-0002-y. Review. No abstract available.

PMID:
29955068
35.

Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model.

Stadlbauer D, Amanat F, Strohmeier S, Nachbagauer R, Krammer F.

Emerg Microbes Infect. 2018 Jun 20;7(1):110. doi: 10.1038/s41426-018-0115-0.

36.

Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge.

Nachbagauer R, Shore D, Yang H, Johnson SK, Gabbard JD, Tompkins SM, Wrammert J, Wilson PC, Stevens J, Ahmed R, Krammer F, Ellebedy AH.

J Virol. 2018 Jul 31;92(16). pii: e00949-18. doi: 10.1128/JVI.00949-18. Print 2018 Aug 15.

37.

Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses.

Pardi N, Hogan MJ, Naradikian MS, Parkhouse K, Cain DW, Jones L, Moody MA, Verkerke HP, Myles A, Willis E, LaBranche CC, Montefiori DC, Lobby JL, Saunders KO, Liao HX, Korber BT, Sutherland LL, Scearce RM, Hraber PT, Tombácz I, Muramatsu H, Ni H, Balikov DA, Li C, Mui BL, Tam YK, Krammer F, Karikó K, Polacino P, Eisenlohr LC, Madden TD, Hope MJ, Lewis MG, Lee KK, Hu SL, Hensley SE, Cancro MP, Haynes BF, Weissman D.

J Exp Med. 2018 Jun 4;215(6):1571-1588. doi: 10.1084/jem.20171450. Epub 2018 May 8.

38.

Antibodies to the Glycoprotein GP2 Subunit Cross-React between Old and New World Arenaviruses.

Amanat F, Duehr J, Oestereich L, Hastie KM, Ollmann Saphire E, Krammer F.

mSphere. 2018 May 2;3(3). pii: e00189-18. doi: 10.1128/mSphere.00189-18. eCollection 2018 May-Jun.

39.

Universal influenza virus vaccines and therapeutics: where do we stand with influenza B virus?

Tan J, Asthagiri Arunkumar G, Krammer F.

Curr Opin Immunol. 2018 Aug;53:45-50. doi: 10.1016/j.coi.2018.04.002. Epub 2018 Apr 17. Review.

PMID:
29677684
40.

Broad cross-reactive IgG responses elicited by adjuvanted vaccination with recombinant influenza hemagglutinin (rHA) in ferrets and mice.

Wang J, Hilchey SP, DeDiego M, Perry S, Hyrien O, Nogales A, Garigen J, Amanat F, Huertas N, Krammer F, Martinez-Sobrido L, Topham DJ, Treanor JJ, Sangster MY, Zand MS.

PLoS One. 2018 Apr 11;13(4):e0193680. doi: 10.1371/journal.pone.0193680. eCollection 2018.

41.

Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies.

Chen YQ, Wohlbold TJ, Zheng NY, Huang M, Huang Y, Neu KE, Lee J, Wan H, Rojas KT, Kirkpatrick E, Henry C, Palm AE, Stamper CT, Lan LY, Topham DJ, Treanor J, Wrammert J, Ahmed R, Eichelberger MC, Georgiou G, Krammer F, Wilson PC.

Cell. 2018 Apr 5;173(2):417-429.e10. doi: 10.1016/j.cell.2018.03.030.

42.

An immuno-assay to quantify influenza virus hemagglutinin with correctly folded stalk domains in vaccine preparations.

Rajendran M, Sun W, Comella P, Nachbagauer R, Wohlbold TJ, Amanat F, Kirkpatrick E, Palese P, Krammer F.

PLoS One. 2018 Apr 4;13(4):e0194830. doi: 10.1371/journal.pone.0194830. eCollection 2018.

43.

NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?

Krammer F, Fouchier RAM, Eichelberger MC, Webby RJ, Shaw-Saliba K, Wan H, Wilson PC, Compans RW, Skountzou I, Monto AS.

MBio. 2018 Apr 3;9(2). pii: e02332-17. doi: 10.1128/mBio.02332-17. Review.

44.

Broadly protective anti-hemagglutinin stalk antibodies induced by live attenuated influenza vaccine expressing chimeric hemagglutinin.

Isakova-Sivak I, Korenkov D, Smolonogina T, Kotomina T, Donina S, Matyushenko V, Mezhenskaya D, Krammer F, Rudenko L.

Virology. 2018 May;518:313-323. doi: 10.1016/j.virol.2018.03.013. Epub 2018 Mar 22.

45.

Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.

Tete SM, Jul-Larsen Å, Rostami S, Lunde THF, Søland H, Krammer F, Cox RJ.

Vaccine. 2018 Apr 12;36(16):2213-2219. doi: 10.1016/j.vaccine.2018.02.022. Epub 2018 Mar 13.

PMID:
29548607
46.

H5N2 vaccine viruses on Russian and US live attenuated influenza virus backbones demonstrate similar infectivity, immunogenicity and protection in ferrets.

Czakó R, Vogel L, Sutton T, Matsuoka Y, Krammer F, Chen Z, Jin H, Subbarao K.

Vaccine. 2018 Mar 27;36(14):1871-1879. doi: 10.1016/j.vaccine.2018.02.061. Epub 2018 Mar 1.

47.

Stable incorporation of GM-CSF into dissolvable microneedle patch improves skin vaccination against influenza.

Littauer EQ, Mills LK, Brock N, Esser ES, Romanyuk A, Pulit-Penaloza JA, Vassilieva EV, Beaver JT, Antao O, Krammer F, Compans RW, Prausnitz MR, Skountzou I.

J Control Release. 2018 Apr 28;276:1-16. doi: 10.1016/j.jconrel.2018.02.033. Epub 2018 Feb 26.

48.

Tick-Borne Encephalitis Virus Vaccine-Induced Human Antibodies Mediate Negligible Enhancement of Zika Virus Infection InVitro and in a Mouse Model.

Duehr J, Lee S, Singh G, Foster GA, Krysztof D, Stramer SL, Bermúdez González MC, Menichetti E, Geretschläger R, Gabriel C, Simon V, Lim JK, Krammer F.

mSphere. 2018 Feb 7;3(1). pii: e00011-18. doi: 10.1128/mSphereDirect.00011-18. eCollection 2018 Jan-Feb.

49.

Influenza B virus reverse genetic backbones with improved growth properties in the EB66® cell line as basis for vaccine seed virus generation.

White KM, Ayllon J, Mena I, Potenski A, Krammer F, García-Sastre A.

Vaccine. 2018 Feb 21;36(9):1146-1153. doi: 10.1016/j.vaccine.2018.01.050. Epub 2018 Feb 1.

PMID:
29395518
50.

Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk-Specific Antibodies Mediating Antibody-Dependent Cellular Cytoxicity.

de Vries RD, Nieuwkoop NJ, van der Klis FRM, Koopmans MPG, Krammer F, Rimmelzwaan GF.

J Infect Dis. 2017 Dec 27;217(1):3-11. doi: 10.1093/infdis/jix546.

Supplemental Content

Loading ...
Support Center